Valeant and its now-outgoing chief executive Michael Pearson pursued quick, aggressive price increases on acquired drugs in recent years—a strategy that is evident in documents collected during a Senate investigation.
WSJ.com: What's News US, Wall Street Journal
Sun, 05/01/2016 - 5:39pm
Valeant and its now-outgoing chief executive Michael Pearson pursued quick, aggressive price increases on acquired drugs in recent years—a strategy that is evident in documents collected during a Senate investigation.